11.06.2012 - The Innovative Medicines Initiative (IMI) has announced details on seven projects funded with a total budget of €215m.
The projects funded within the next five years include two coordinated by GlaxoSmithKline plc: model-based preclinical development of anti-tuberculosis (TB) drug combinations (PreDiCT-TB), which aim to make tuberculosis treatments more patient-friendly; and development of tools to predict immune response to biopharmaceuticals (ABIRISK). Sanofi is coordinating the DIRECT project to research patient stratification for personalised Type II diabetes treatments. Novartis AG and The University of Surrey (UK) are working on a project to develop biomarkers to test the safety of vaccines (BIOVACSAFE). A project coordinated by AstraZeneca plc is to develop tests for drug-induced liver injury (MIP-DILI); and one consortium coordinated by Roche seeks to develop research tools and diagnostics for autism spectrum disorder (EU-AIMS).
IMI also announced the launch of a Education and Training project called EUPATI, which shall create a European Patients’ Academy on Therapeutic Innovation. Its aim is to educate patients and the public about medicines development and empower patients to engage more effectively in the drug development process. The new projects mean that IMI is now supporting a total of 30 projects with a combined total cost of over €650m. IMI is a public-private partnership in health research and development. The European Union contributes €1 bn to the IMI research programme, which is matched by contributions worth at least another €1bn from the member companies of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
28.01.2015 EMA recommends suspending around 750 generic medicines marketed throughout the world after India’s GVK Biosciences is accused of faking bioequivalence studies. Meds considered critically important for patients will remain available.
20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck.
13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.
09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.